Clinical Trial

Zilganersen Expanded Access Program for Individuals With Alexander Disease

Name: Zilganersen Expanded Access Program for Individuals With Alexander Disease — clinical trial record (NCT07487389)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Available

View on ClinicalTrials.gov →

Summary

The purpose of the expanded access program (EAP) is to provide access to zilganersen for eligible individuals with Alexander disease (AxD).

Trial Details

NCT Number	NCT07487389
Lead Sponsor	Ionis Pharmaceuticals, Inc.
Conditions	Alexander Disease
Updated on ClinicalTrials.gov	2026-03-23